Last reviewed · How we verify
Plasma-derived antithrombin
Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors.
Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors. Used for Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery.
At a glance
| Generic name | Plasma-derived antithrombin |
|---|---|
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | Anticoagulant |
| Target | Thrombin, Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action is based on the protein's ability to bind to and inactivate key enzymes in the coagulation cascade, thereby preventing the formation of blood clots. Antithrombin has a high affinity for thrombin and other coagulation factors, making it an effective inhibitor of coagulation.
Approved indications
- Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery
Common side effects
- Hemorrhage
- Thrombocytopenia
Key clinical trials
- Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass (PHASE3)
- Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate (PHASE2, PHASE3)
- An Open-label Study of KW-3357 (PHASE3)
- Antithrombin III in Infants With Cardiopulmonary Bypass (CPB) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma-derived antithrombin CI brief — competitive landscape report
- Plasma-derived antithrombin updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI